This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dearden C . Disease-specific complications of chronic lymphocytic leukemia. Hematology 2008; 2008: 450–456.
Diehl LF, Ketchum LH . Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97.
Cines DB, Bussel JB, Liebman HA, Luning Prak ET . The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113: 6511–6521.
Harrington WJ, Minnich V, Hollingsworth JW, Moore CV . Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38: 1–10.
Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887–895.
Nurden AT, Viallard J-F, Nurden P . New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 2009; 373: 1562–1569.
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641–648.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371: 395–403.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Michael J Keating is a consultant for GlaxcoSmithKline. William G Wierda received research funding from and has served as a consultant for GlaxcoSmithKline. Stefan Koehrer has no conflict of interest to disclose.
Additional information
Author contributions
Stefan Koehrer reviewed, analyzed, summarized patient data, wrote paper and approved the final version of the paper. Michael J Keating was the treating physician for patients and approved the final version of the paper. William G Wierda was the treating physician for patients, and reviewed, analyzed, summarized patient data, wrote paper and approved the final version of the paper.
Rights and permissions
About this article
Cite this article
Koehrer, S., Keating, M. & Wierda, W. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 24, 1096–1098 (2010). https://doi.org/10.1038/leu.2010.45
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.45
This article is cited by
-
Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura
Annals of Hematology (2017)
-
A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
Current Hematologic Malignancy Reports (2017)
-
Romiplostim overcomes refractory secondary immune thrombocytopenia in a patient affected by serous ovarian carcinoma
International Cancer Conference Journal (2012)